Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513348 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL21512638 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL30866883 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL29969142 | 0.83 | HRH3 (0.42) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL21512755 | 0.83 | HRH3 (0.42) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL21513351 | 0.81 | CYP1A2 (0.47) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL29969817 | 0.81 | CYP1A2 (0.47) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL21513728 | 0.80 | HRH3 (0.40) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL21512599 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL1816280 | 0.78 | TSHR (0.40) | KDM4EALDH1A1CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | KDM4E 1653/4885ALDH1A1 3354/4885CYP1A2 3864/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | KDM4E 1653/4885ALDH1A1 3354/4885CYP1A2 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.